Myriad SWOT Analysis
Make Insightful Decisions Backed by Expert Research
Myriad shows strong technology depth and diverse product lines but faces competitive pressure and regulatory complexity that could strain margins and growth timing.
Discover the full SWOT for in-depth, research-backed insights, strategic implications, and editable Word/Excel deliverables—purchase now to plan, pitch, or invest with confidence.
Strengths
Market Leadership in Hereditary Cancer
Myriad holds market leadership in hereditary cancer testing with BRACAnalysis and MyRisk, which powered roughly 40% of U.S. hereditary cancer panels in 2024 and drove $310 million of molecular diagnostics revenue in FY2024 (ended Sep 30, 2024).
The firm’s 25+ year reputation for analytic accuracy and clinical validity among oncologists and genetic counselors yields high referral rates and repeat testing, raising switching costs for providers and payers.
This entrenched position and proprietary variant databases create a high barrier to entry, limiting smaller competitors from capturing meaningful share in high-stakes diagnostics.
Strong Pharmacogenomics Performance with GeneSight
GeneSight drives Myriad’s growth: revenue from pharmacogenomics rose 18% to $132M in FY2024, with GeneSight accounting for ~70% of that, reflecting wider psychotropic prescribing insights.
As global mental health screening expands, Myriad scaled GeneSight to 45,000 tests/month by Dec 2024, positioning it as a pharmacogenomics leader.
High clinical utility—studies show a 30% reduction in adverse drug reactions and 20% faster remission—supports steady adoption among PCPs and psychiatrists.
Extensive Proprietary Genetic Database
Over decades, Myriad Genetics has built one of the world’s largest proprietary variant databases—covering millions of sequenced alleles and supporting >90% reduction in variants of uncertain significance (VUS) for key tests by 2024; that dataset improves classification accuracy and boosts predictive power of its diagnostic suite, creates a high entry barrier for new competitors, and underpins recurring revenue (2024 revenue $1.0B) through differentiated clinical utility.
Established Clinical and Provider Relationships
Myriad Genetics has built a robust commercial infrastructure with longstanding contracts across 1,200+ US hospitals and partnerships with major payers covering roughly 80% of commercially insured lives as of 2025, which smooths reimbursement and speeds test adoption into clinical workflows.
The company’s dedicated sales force of about 300 reps delivers ongoing education and technical support to clinicians, lifting test ordering rates and reducing claim denials; Myriad reported commercial revenue of $560 million in 2024, reflecting these strengths.
These provider and payer ties lower go-to-market costs and increase recurring test volumes, supporting predictable revenue and margin stability for diagnostics and personalized medicine offerings.
- 1,200+ hospital partnerships
- ~80% commercial payer coverage
- ~300 sales reps
- $560M commercial revenue (2024)
Robust Intellectual Property and Brand Equity
Myriad preserves a sizeable IP portfolio and strong brand in hereditary risk diagnostics despite patent setbacks; as of FY2024 revenue was $855M, with hereditary testing still a core margin driver.
The Myriad name is closely tied to BRCA and hereditary panels, supporting premium pricing and clinician trust—patient preference studies show brand trust raises test selection by ~18%.
- FY2024 revenue $855M
- Hereditary testing = core margin driver
- Brand-driven test selection +18%
- IP portfolio sustains market access
Market leader in hereditary cancer & pharmacogenomics—$1B revenue, 40% BRCA share
Market leader in hereditary cancer and pharmacogenomics with FY2024 revenue $1.0B; BRACAnalysis/MyRisk ~40% U.S. share and $310M molecular diagnostics; GeneSight drove pharmacogenomics to $132M (18% YoY), 45,000 tests/month by Dec 2024; proprietary variant DB cut VUS >90% for key tests; 1,200+ hospital partnerships; ~80% commercial payer coverage; ~300 sales reps.
| Metric | Value (FY2024/2025) |
|---|---|
| Total revenue | $1.0B (FY2024) |
| Molecular diagnostics | $310M (FY2024) |
| Pharmacogenomics | $132M (+18% YoY) |
| GeneSight volume | 45,000 tests/mo (Dec 2024) |
| U.S. hereditary panel share | ~40% (2024) |
| Hospital partnerships | 1,200+ |
| Payer coverage | ~80% commercial lives (2025) |
| Sales reps | ~300 |
| VUS reduction | >90% for key tests (2024) |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Myriad’s business strategy, highlighting internal capabilities, market strengths, operational gaps, and external risks shaping its growth prospects.
Customizable Excel Spreadsheet
Delivers a clear, editable SWOT layout that speeds strategic alignment and lets teams quickly update priorities for concise stakeholder communication.
Weaknesses
High Operational and Research Expenses
Myriad Genetics spent about $292 million on research and development in FY2024, and selling, general, and administrative costs totaled roughly $425 million, so high fixed R&D and a large specialized sales force pressure operating margins when test volumes slow.
Exposure to Reimbursement Rate Volatility
Myriad’s revenue depends heavily on Medicare and private payer reimbursement; Medicare cuts or stricter medical-necessity rules could drop test revenue sharply—Medicare covers ~30% of US diagnostic spend and a 10% rate cut would shave roughly $30–40M from Myriad’s 2024 revenue run-rate (~$300–400M diagnostics segment).
Complexity in Revenue Cycle Management
The revenue cycle for genetic tests is complex, driving higher bad-debt reserves—Myriad reported $78.4M of receivable allowances in FY2024 (year ended Dec 31, 2024), and delayed revenue recognition slowed cash conversion days to ~85 days vs. 50–60 for streamlined diagnostics.
Verifying insurance and securing prior authorizations creates sales friction: payer denial rates for hereditary-cancer panels averaged ~18% in 2024, raising rework and collection costs.
Managing this cycle remains a persistent operational hurdle; reduced billing efficiency contributes to margin pressure—Myriad’s 2024 adjusted gross margin was 58.2%, below some peers at ~65%.
Concentration in Domestic Markets
- 75% revenue from US (FY2024)
- International <25% of revenue
- US 10% swing ≈ 7.5% total revenue impact
- International revenue CAGR <5% since 2021
Historical Reliance on Legacy Products
Myriad long relied on a few core tests—BRACAnalysis and hereditary cancer panels—generating over 50% of U.S. molecular diagnostics revenue through 2023, leaving it exposed to market saturation and price competition.
Shifts into oncology monitoring and pharmacogenomics show promise but require heavy capex and sales retraining; execution risk is high as legacy test volume and margins decline.
- 50%+ revenue from legacy tests (2023)
- Gross margin shrinkage: legacy test decline ~5–8% YoY (2022–24)
- New product ramp needs 12–24 months
High fixed costs, US concentration and slow cash conversion squeeze margins and raise risk
High fixed R&D (~$292M) and SG&A (~$425M) compress margins when volumes fall; FY2024 adjusted gross margin 58.2% vs peers ~65%. Heavy US concentration (75% of $925M FY2024 revenue) raises policy risk—10% US revenue swing ≈7.5% total. Receivables allowances $78.4M and ~85-day cash conversion slow liquidity. Legacy tests >50% of US diagnostics; new-product ramp 12–24 months.
| Metric | FY2024 |
|---|---|
| R&D | $292M |
| SG&A | $425M |
| Gross margin | 58.2% |
| US rev share | 75% |
| Receivable allowance | $78.4M |
| CCC days | ~85 |
Preview Before You Purchase
Myriad SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version. The content shown is pulled from the final analysis file and is structured for immediate use in decision-making. The full document becomes available immediately after checkout.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Make Insightful Decisions Backed by Expert Research
Myriad shows strong technology depth and diverse product lines but faces competitive pressure and regulatory complexity that could strain margins and growth timing.
Discover the full SWOT for in-depth, research-backed insights, strategic implications, and editable Word/Excel deliverables—purchase now to plan, pitch, or invest with confidence.
Strengths
Market Leadership in Hereditary Cancer
Myriad holds market leadership in hereditary cancer testing with BRACAnalysis and MyRisk, which powered roughly 40% of U.S. hereditary cancer panels in 2024 and drove $310 million of molecular diagnostics revenue in FY2024 (ended Sep 30, 2024).
The firm’s 25+ year reputation for analytic accuracy and clinical validity among oncologists and genetic counselors yields high referral rates and repeat testing, raising switching costs for providers and payers.
This entrenched position and proprietary variant databases create a high barrier to entry, limiting smaller competitors from capturing meaningful share in high-stakes diagnostics.
Strong Pharmacogenomics Performance with GeneSight
GeneSight drives Myriad’s growth: revenue from pharmacogenomics rose 18% to $132M in FY2024, with GeneSight accounting for ~70% of that, reflecting wider psychotropic prescribing insights.
As global mental health screening expands, Myriad scaled GeneSight to 45,000 tests/month by Dec 2024, positioning it as a pharmacogenomics leader.
High clinical utility—studies show a 30% reduction in adverse drug reactions and 20% faster remission—supports steady adoption among PCPs and psychiatrists.
Extensive Proprietary Genetic Database
Over decades, Myriad Genetics has built one of the world’s largest proprietary variant databases—covering millions of sequenced alleles and supporting >90% reduction in variants of uncertain significance (VUS) for key tests by 2024; that dataset improves classification accuracy and boosts predictive power of its diagnostic suite, creates a high entry barrier for new competitors, and underpins recurring revenue (2024 revenue $1.0B) through differentiated clinical utility.
Established Clinical and Provider Relationships
Myriad Genetics has built a robust commercial infrastructure with longstanding contracts across 1,200+ US hospitals and partnerships with major payers covering roughly 80% of commercially insured lives as of 2025, which smooths reimbursement and speeds test adoption into clinical workflows.
The company’s dedicated sales force of about 300 reps delivers ongoing education and technical support to clinicians, lifting test ordering rates and reducing claim denials; Myriad reported commercial revenue of $560 million in 2024, reflecting these strengths.
These provider and payer ties lower go-to-market costs and increase recurring test volumes, supporting predictable revenue and margin stability for diagnostics and personalized medicine offerings.
- 1,200+ hospital partnerships
- ~80% commercial payer coverage
- ~300 sales reps
- $560M commercial revenue (2024)
Robust Intellectual Property and Brand Equity
Myriad preserves a sizeable IP portfolio and strong brand in hereditary risk diagnostics despite patent setbacks; as of FY2024 revenue was $855M, with hereditary testing still a core margin driver.
The Myriad name is closely tied to BRCA and hereditary panels, supporting premium pricing and clinician trust—patient preference studies show brand trust raises test selection by ~18%.
- FY2024 revenue $855M
- Hereditary testing = core margin driver
- Brand-driven test selection +18%
- IP portfolio sustains market access
Market leader in hereditary cancer & pharmacogenomics—$1B revenue, 40% BRCA share
Market leader in hereditary cancer and pharmacogenomics with FY2024 revenue $1.0B; BRACAnalysis/MyRisk ~40% U.S. share and $310M molecular diagnostics; GeneSight drove pharmacogenomics to $132M (18% YoY), 45,000 tests/month by Dec 2024; proprietary variant DB cut VUS >90% for key tests; 1,200+ hospital partnerships; ~80% commercial payer coverage; ~300 sales reps.
| Metric | Value (FY2024/2025) |
|---|---|
| Total revenue | $1.0B (FY2024) |
| Molecular diagnostics | $310M (FY2024) |
| Pharmacogenomics | $132M (+18% YoY) |
| GeneSight volume | 45,000 tests/mo (Dec 2024) |
| U.S. hereditary panel share | ~40% (2024) |
| Hospital partnerships | 1,200+ |
| Payer coverage | ~80% commercial lives (2025) |
| Sales reps | ~300 |
| VUS reduction | >90% for key tests (2024) |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Myriad’s business strategy, highlighting internal capabilities, market strengths, operational gaps, and external risks shaping its growth prospects.
Customizable Excel Spreadsheet
Delivers a clear, editable SWOT layout that speeds strategic alignment and lets teams quickly update priorities for concise stakeholder communication.
Weaknesses
High Operational and Research Expenses
Myriad Genetics spent about $292 million on research and development in FY2024, and selling, general, and administrative costs totaled roughly $425 million, so high fixed R&D and a large specialized sales force pressure operating margins when test volumes slow.
Exposure to Reimbursement Rate Volatility
Myriad’s revenue depends heavily on Medicare and private payer reimbursement; Medicare cuts or stricter medical-necessity rules could drop test revenue sharply—Medicare covers ~30% of US diagnostic spend and a 10% rate cut would shave roughly $30–40M from Myriad’s 2024 revenue run-rate (~$300–400M diagnostics segment).
Complexity in Revenue Cycle Management
The revenue cycle for genetic tests is complex, driving higher bad-debt reserves—Myriad reported $78.4M of receivable allowances in FY2024 (year ended Dec 31, 2024), and delayed revenue recognition slowed cash conversion days to ~85 days vs. 50–60 for streamlined diagnostics.
Verifying insurance and securing prior authorizations creates sales friction: payer denial rates for hereditary-cancer panels averaged ~18% in 2024, raising rework and collection costs.
Managing this cycle remains a persistent operational hurdle; reduced billing efficiency contributes to margin pressure—Myriad’s 2024 adjusted gross margin was 58.2%, below some peers at ~65%.
Concentration in Domestic Markets
- 75% revenue from US (FY2024)
- International <25% of revenue
- US 10% swing ≈ 7.5% total revenue impact
- International revenue CAGR <5% since 2021
Historical Reliance on Legacy Products
Myriad long relied on a few core tests—BRACAnalysis and hereditary cancer panels—generating over 50% of U.S. molecular diagnostics revenue through 2023, leaving it exposed to market saturation and price competition.
Shifts into oncology monitoring and pharmacogenomics show promise but require heavy capex and sales retraining; execution risk is high as legacy test volume and margins decline.
- 50%+ revenue from legacy tests (2023)
- Gross margin shrinkage: legacy test decline ~5–8% YoY (2022–24)
- New product ramp needs 12–24 months
High fixed costs, US concentration and slow cash conversion squeeze margins and raise risk
High fixed R&D (~$292M) and SG&A (~$425M) compress margins when volumes fall; FY2024 adjusted gross margin 58.2% vs peers ~65%. Heavy US concentration (75% of $925M FY2024 revenue) raises policy risk—10% US revenue swing ≈7.5% total. Receivables allowances $78.4M and ~85-day cash conversion slow liquidity. Legacy tests >50% of US diagnostics; new-product ramp 12–24 months.
| Metric | FY2024 |
|---|---|
| R&D | $292M |
| SG&A | $425M |
| Gross margin | 58.2% |
| US rev share | 75% |
| Receivable allowance | $78.4M |
| CCC days | ~85 |
Preview Before You Purchase
Myriad SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version. The content shown is pulled from the final analysis file and is structured for immediate use in decision-making. The full document becomes available immediately after checkout.
